(redirected from Doxorubicin hydrochloride)
Also found in: Thesaurus, Medical.


 (lĭp′ə-sōm′, lī′pə-)
A microscopic artificial vesicle consisting of an aqueous core enclosed in phospholipid molecules, used to convey vaccines, drugs, or other substances to target tissues.

lip′o·so′mal adj.


of or relating to liposomes
References in periodicals archive ?
M2 EQUITYBITES-May 17, 2017-Dr Reddy's gains US FDA approval to launch its doxorubicin hydrochloride liposome injection
M2 PHARMA-May 17, 2017-Dr Reddy's gains US FDA approval to launch its doxorubicin hydrochloride liposome injection
Libod, also known as doxorubicin hydrochloride liposome injection, is a product produced by Fudan-Zhangjiang Bio-Pharmaceutical Co.
Exir Nano Sina Company is another firm which has presented products, including Sina Curcumin 80, Sina Ampholish and liposomal doxorubicin hydrochloride (Sina Doxosome) which was introduced as one of the top three nanoproducts in the country in the 7th Nanotechnology Awards Ceremony in 2014.
Commercial available doxorubicin is a classical chemotherapeutic agent for cancer treatment and its salt, doxorubicin hydrochloride, is highly water soluble and can be good for pharmacological applications (Chabner et al.
3% (OTC) Mupirocin Cream USP, 2% Glenmark Rosiglitazone Maleate Tablets, 2 mg (base), Teva 4 mg (base), 8 mg (base) FEBRUARY 2013 Doxorubicin Hydrochloride Liposome Sun Pharma Injection LISP, 2 mg/ml, packaged in 20 mg/10 ml and 50 mg/25 ml single-use vials Mafenide Acetate, USP for 5% Topical Par Pharmaceutical Solution, 50 g sterile powder per packet Fludeoxyglucose F18 Injection USP, Houston Cyclotron 20-500 mci/ml @ EOS Partners Buprenorphine HCI and Naloxone HCI Amneal Dihydrate Sublingual Tablets, 2 mg (base)/0.
Preparation of doxorubicin solution: Doxorubicin hydrochloride (Farmitalia, Italy) was dissolved in distilled water so that the final concentration was 20 [micro]g/ml.
Doxorubicin hydrochloride liposome injection is currently on the FDA's drug shortage list of supply.
In the other 33 patients, doxorubicin hydrochloride or epirubicin hydrochloride (10-20 mg/m2) were injected every 2-4 weeks in a "one-shot" manner.
To combat these odds, Marcus and his colleaues gave high-risk patients -- those with tumors larger than 10 centimeters and evidence of cancer spread -- five cycles of standard chemotherapy consisting of vincristine, cyclophosphamide and doxorubicin hydrochloride.
APP also launched Doxorubicin Hydrochloride Injection, the generic equivalent of Adriamycin([R]), which is owned by Bedford Laboratories GmbH.